Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab + doxorubicin
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous, Subcutaneous
01
Overview
Trastuzumab + doxorubicin is a combination therapy used primarily in the treatment of HER2-overexpressing breast cancer. Trastuzumab is a humanized monoclonal antibody that selectively binds to the extracellular domain of the human epidermal growth factor receptor 2 (HER2), inhibiting its dimerization and downstream signaling, which suppresses cancer cell growth and survival. Doxorubicin is an anthracycline antibiotic that intercalates DNA, inhibits topoisomerase II, and generates free radicals leading to cytotoxicity. The combination leverages trastuzumab’s targeted anti-HER2 activity with doxorubicin’s broad cytotoxic effects for synergistic efficacy in HER2-positive cancers[1][4][5][6].
- Other names
- trastuzumab + doxorubicin
02
Targets
DNATOP2A (DNA topoisomerase II)
Beyond the preview
Go deeper on trastuzumab + doxorubicin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab + doxorubicin.